Kelly Weselman, MD
Rheumatology · Woodstock, GANPI 1952370801
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 96 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,278, 5.5 times the $234 reported in 2023. That places this record below the midpoint for rheumatology clinicians in GA, where the typical reported total is $5,560.
Across 96 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$354
- GSK$224
- Novartis$161
- UCB, Inc.$151
- AbbVie$147
- E.r. Squibb & Sons, L.L.C.$138
- plus $933 from 18 others
What the payments were for
- Food & beverage$2,03496%
- Education$744%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 19 | $354 |
| GSK | 15 | $224 |
| Novartis | 7 | $161 |
| UCB, Inc. | 7 | $151 |
| AbbVie | 6 | $147 |
| E.r. Squibb & Sons, L.L.C. | 6 | $138 |
| Johnson & Johnson(2 entities) | 5 | $112 |
| Actelion Pharmaceuticals US, Inc. | 3 | $100 |
| United Therapeutics Corporation | 1 | $98 |
| Boehringer Ingelheim | 2 | $90 |
| Sobi, Inc | 4 | $81 |
| Aurinia Pharma U.S., Inc. | 3 | $78 |
| Radius Health, Inc. | 3 | $71 |
| Mallinckrodt Hospital Products Inc. | 2 | $54 |
| AstraZeneca | 2 | $46 |
| Organon | 2 | $34 |
| Genentech USA, Inc. | 2 | $32 |
| Lilly USA, LLC | 1 | $25 |
| Fresenius Kabi USA, LLC | 1 | $24 |
| Invivyd Inc | 1 | $22 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Pfizer | 1 | $18 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
How this compares
$2,108 in reported general payments places this provider in the 30th percentile of 177 rheumatology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 20 | $158,602 |
| Enbrel SureclickEtanercept | 16 | $115,191 |
| Hydroxychloroquine Sulfate | 88 | $3,469 |
| MethotrexateMethotrexate Sodium | 103 | $1,799 |
| Leflunomide | 16 | $1,002 |
| Prednisone | 60 | $619 |
| Diclofenac Sodium | 11 | $275 |
| Omeprazole | 21 | $173 |
| Tramadol Hcl | 37 | $167 |
| Gabapentin | 14 | $150 |
| Alendronate Sodium | 16 | $74 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Woodstock
- Naveen RajWoodstock$27K
- James MossellTifton$1.6M
- Gary MyersonAtlanta$1M
- Theresa Lawrence FordLawrenceville$410K
- William WilsonAtlanta$344K
- Jefrey LiebermanDecatur$247K
- Mohammed AbubakerMarietta$218K
- James HuntThomasville$160K
- Omar KhanCumming$145K
- Paul SutejAtlanta$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.